167 related articles for article (PubMed ID: 10761999)
1. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population.
Marcus PM; Vineis P; Rothman N
Pharmacogenetics; 2000 Mar; 10(2):115-22. PubMed ID: 10761999
[TBL] [Abstract][Full Text] [Related]
2. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
[TBL] [Abstract][Full Text] [Related]
3. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
4. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
[TBL] [Abstract][Full Text] [Related]
5. Differential association for N-acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population.
Quan L; Chattopadhyay K; Nelson HH; Chan KK; Xiang YB; Zhang W; Wang R; Gao YT; Yuan JM
Oncotarget; 2016 Jun; 7(26):40012-40024. PubMed ID: 27223070
[TBL] [Abstract][Full Text] [Related]
6. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.
Lubin JH; Kogevinas M; Silverman D; Malats N; Garcia-Closas M; Tardón A; Hein DW; Garcia-Closas R; Serra C; Dosemeci M; Carrato A; Rothman N
Int J Epidemiol; 2007 Feb; 36(1):236-41. PubMed ID: 17510079
[TBL] [Abstract][Full Text] [Related]
7. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
Wu H; Wang X; Zhang L; Mo N; Lv Z
Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
[TBL] [Abstract][Full Text] [Related]
8. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
Moore LE; Baris DR; Figueroa JD; Garcia-Closas M; Karagas MR; Schwenn MR; Johnson AT; Lubin JH; Hein DW; Dagnall CL; Colt JS; Kida M; Jones MA; Schned AR; Cherala SS; Chanock SJ; Cantor KP; Silverman DT; Rothman N
Carcinogenesis; 2011 Feb; 32(2):182-9. PubMed ID: 21037224
[TBL] [Abstract][Full Text] [Related]
9. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.
Pesch B; Gawrych K; Rabstein S; Weiss T; Casjens S; Rihs HP; Ding H; Angerer J; Illig T; Klopp N; Bueno-de-Mesquita B; Ros MM; Kaaks R; Chang-Claude J; Roswall N; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Dossus L; Boeing H; Weikert S; Trichopoulos D; Palli D; Sieri S; Tumino R; Panico S; Quirós JR; González C; Sánchez MJ; Dorronsoro M; Navarro C; Barricarte A; Ljungberg B; Johansson M; Ulmert D; Ehrnström R; Khaw KT; Wareham N; Key TJ; Ferrari P; Romieu I; Riboli E; Brüning T; Vineis P
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2055-65. PubMed ID: 24092628
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of the relationship between slow acetylation of N-acetyl transferase 2 and the risk of bladder cancer.
An Y; Li H; Wang KJ; Liu XH; Qiu MX; Liao Y; Huang JL; Wang XS
Genet Mol Res; 2015 Dec; 14(4):16896-904. PubMed ID: 26681036
[TBL] [Abstract][Full Text] [Related]
11. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
[TBL] [Abstract][Full Text] [Related]
12. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
13. Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients.
Schnakenberg E; Ehlers C; Feyerabend W; Werdin R; Hübotter R; Dreikorn K; Schloot W
Clin Genet; 1998 May; 53(5):396-402. PubMed ID: 9660060
[TBL] [Abstract][Full Text] [Related]
14. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese.
Inatomi H; Katoh T; Kawamoto T; Matsumoto T
Int J Urol; 1999 Sep; 6(9):446-54. PubMed ID: 10510890
[TBL] [Abstract][Full Text] [Related]
15. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.
Risch A; Wallace DM; Bathers S; Sim E
Hum Mol Genet; 1995 Feb; 4(2):231-6. PubMed ID: 7757072
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer.
Hunter DJ; Hankinson SE; Hough H; Gertig DM; Garcia-Closas M; Spiegelman D; Manson JE; Colditz GA; Willett WC; Speizer FE; Kelsey K
Carcinogenesis; 1997 Nov; 18(11):2127-32. PubMed ID: 9395212
[TBL] [Abstract][Full Text] [Related]
17. Association between N-Acetyltransferase 2 Polymorphism and Bladder Cancer Risk: a Meta-Analysis in a Single Ethnic Group.
Xu WJ; Wen LP; Jiang XX; Ye LY; Meng FH; Guan S; Qian YJ; Wei JF
Clin Lab; 2017 Feb; 63(2):287-293. PubMed ID: 28182356
[TBL] [Abstract][Full Text] [Related]
18. NAT2*5/*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians.
El Desoky ES; AbdelSalam YM; Salama RH; El Akkad MA; Atanasova S; von Ahsen N; Armstrong VW; Oellerich M
Ther Drug Monit; 2005 Jun; 27(3):297-304. PubMed ID: 15905799
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
McGrath M; Michaud D; De Vivo I
BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: occupational and non-occupational bladder cancer patient groups.
Ma QW; Lin GF; Chen JG; Xiang CQ; Guo WC; Golka K; Shen JH
Biomed Environ Sci; 2004 Sep; 17(3):291-8. PubMed ID: 15602826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
